Important note: Information in this article was accurate in November 2003. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - November 2003
Simon Collins, HIV i-Base
Two recently published studies, each based on different interruption protocols, have both shown disappointing results, with higher rates of treatment failure and development of resistance.
The rationale for these studies was that HAART-induced viral suppression could maintain viral benefit to allow short periods off treatment, with potential benefits of reduced toxicity and cost.
The first study, from NIAID, published in 1 August issue of Journal of Infectious Diseases, looked at the effect of long-cycle structured intermittent therapy (SIT). Treatment interrupted for four weeks followed by eight weeks with HAART was compared to continuous HAART. The study was prematurely terminated to new enrolment because of the emergence of genetic mutations associated with resistance to antiretroviral drugs in five patients. After 48 weeks, there was no significant difference between groups in reduced toxicity. There was also no clear autoimmunisation effect by immunologic or virologic parameters.
Results from the Staccato Study, published as a fast track article in the 17 October issue of AIDS, led to the early termination of one arm of this large international study in which 600 patients (from Thailand, Switzerland, Australia, Argentina and Australia) who were on stable HAART (viral load <50 copies/mL, CD4 >350 cells/mm3) were randomised 1:1:1 to either alternating one week on treatment with one week off, interrupting treatment and restarting by CD4 count or remaining on continuous treatment.
An interim analysis was performed after 150 patients had enroled which included 36 patients in the week-on week-off arm with 8-week data. Overall, 19/36 (53%) patients failed using this regimen. Early failures (within 12 weeks) included three out of four patients on triple nucleotides in Switzerland, and in 11 out of 17 patients on ddI/d4T/saquinavir/ritonavir in Thailand. ‘Late’ failures (after 12 weeks) included two patients on nelfinavir/3TC/AZT, one on saquinavir/ritonavir/d4T and one on nevirapine/3TC/AZT. Of eight patients on efavirenz/3TC/AZT, one has failed.
In the continuous treatment arm of the study, only two failures have occurred so far in 37 patients (P < 0.001, compared to the one-week-one-1-week-off). In the CD4-guided arm, no failures occurred in 39 patients. The week-on week-off arm of this study has now been terminated.
References:
031110
IB30409-19
©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
